Description
Tezspire (tezepelumab-ekko) is a prescription medication that belongs to the drug class of monoclonal antibodies. It is used to treat severe asthma in adults and children 12 years of age and older whose condition cannot be managed by their existing asthma medication. Tezspire is the first and only biologic approved for severe asthma without phenotypic or biomarker limitations.
Mechanism of Action
Tezspire works by blocking thymic stromal lymphopoietin (TSLP), a cytokine that plays a key role in the inflammatory cascade that leads to asthma symptoms. By blocking TSLP, Tezspire can help to reduce inflammation and improve lung function.
Dosage and Administration
Tezspire is given as a subcutaneous injection every four weeks. The recommended dosage for adults and children 12 years of age and older is 210 mg.
Effectiveness
Tezspire has been shown to be effective in reducing asthma exacerbations and improving lung function in clinical trials. For example, in one study, Tezspire reduced the rate of asthma exacerbations by 55% in patients with severe asthma.
Side Effects
The most common side effects of Tezspire include:
- Headache
- Nasopharyngitis
- Upper respiratory tract infection
- Arthralgia
- Myalgia
- Fatigue
- Back pain
- Diarrhea
- Nausea
- Rash
Tezspire can also cause serious side effects, such as:
- Allergic reactions
- Anaphylaxis
- Injection site reactions
- Eosinophilic pneumonia
- Hypereosinophilia
- Parasitic infections
Contraindications
Tezspire is contraindicated in patients with a known hypersensitivity to tezepelumab or any of the other ingredients in the medication.
Conclusion
Tezspire is an effective treatment for severe asthma in adults and children 12 years of age and older whose condition cannot be managed by their existing asthma medication. It is important to be aware of the potential side effects of Tezspire before starting treatment. Talk to your doctor about the risks and benefits of Tezspire to determine if it is right for you.
Reviews
There are no reviews yet.